Histologic Evaluation of Lung Cancer Invasion: More Difficult Than Meets the Eye
Mary Beth Beasley, MD+more
IASLC Pathology Committee members say the identification and evaluation of features that result in discordance in measuring invasive tumor size will hopefully improve reproducibility and lead to more accurate tumor staging moving forward. Read more
Optimal Pathologic Staging of Lung Cancer Depends on More Than the Pathologist
Mary Beth Beasley, MDPathology—and pathologic staging in particular—can be improved through multidisciplinary efforts. Read more
Low-Dose CT, ctDNA May Partner for Lung Cancer Detection
Leah LawrenceLiquid biopsy tool may be useful in high-risk individuals unwilling or unable to undergo LDCT. Read more
Award Lecture Highlights Tumor Evolution Through Liquid Biopsy
Leah LawrenceThe UK’s Dr. Charles Swanton received the ISLB’s 2021 award for outstanding scientific contribution. Read more
Enhancing Understanding of Testing Applications, Best Practices: A Q&A with Dr. Lynette M. Sholl
Lynette M. Sholl, MDLynette M. Sholl, MD, Chief of Thoracic Pathology and Associate Director of the Center for Advanced Molecular Diagnostics at Brigham and Women’s Hospital and Associate Professor at Harvard Medical School, […] Read more
All information and materials presented on or through IASLC’s websites, or made available or provided by or on behalf of IASLC during any webinar, seminar, or other event or activity, […] Read more
Multidisciplinary EURACAN/IASLC Proposal for Revision of the Histologic Classification of Malignant Pleural Mesothelioma
Sanja Dacic+more
Sponsored by EURACAN and the IASLC, a multidisciplinary group comprised of pathologists, oncologists, surgeons, radiologists, and molecular biologists met July 5 and 6, 2018, to critically review the current histologic […] Read more
Improving Molecular Testing in Lung Cancer: What We Learned From the IASLC Global Survey
Matthew P. Smeltzer, PhD+more
The past 10 years have seen a dramatic increase in novel therapeutic options for patients with lung cancer, with many treatments now personalized to the specific tumor characteristics of each […] Read more
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapies
Sanja Dacic+more
Treatment guidelines recommend neoadjuvant or adjuvant therapies with surgery for patients with large primary tumors or clinical evidence of intrathoracic nodal spread.1,2 A recent joint IASLC–U.S. Food and Drug Administration […] Read more
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD Posted: April 16, 2020 Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity, are […] Read more